SAfety and TOlerance of the Biopsies in Auto-immune Rare dIseases
NCT ID: NCT05022420
Last Updated: 2024-04-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
600 participants
OBSERVATIONAL
2021-08-19
2025-02-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
B-dependant Rare AutoImmune diseaSES - Cohort of Patients With Suspected Diagnosis of Primitive Sjögren Syndrome
NCT04931160
Auto-immune Diseases and Quality of Life
NCT02855840
Evaluation of the Prevalence of BP180 and BP230 Autoantibodies in the Serum of Patients With Pruritus Under Immunotherapy
NCT05689463
Tolerance and Efficacy of Rituximab in Sjogren's Disease
NCT00740948
Anti-nucleosome B Lymphocytes in Lupus
NCT01889654
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Salivary gland biospy,
100 Salivary gland biospy use for the diagnosis of sjogern disease or other auto-immune disease.
No interventions assigned to this group
muscular biopsy,
muscular biospy use for the diagnosis of muscular auto-immune disease.
No interventions assigned to this group
neuro muscular biospy
neuro muscular biospy use for the diagnosis of vasculitis,muscular auto-immune disease or neuro-muscumar auto-immune disease
No interventions assigned to this group
temporal arteries biospy
temporal arteries biospy uses for the diagnosis of giant cell arteritis
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Brest
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU d'ANGERS
Angers, , France
CHU de Bordeaux
Bordeaux, , France
CHRU de Brest
Brest, , France
CHU de LILLE
Lille, , France
CHU de Marseille
Marseille, , France
Hôpital de la Salpétrière
Paris, , France
CH de Quimper
Quimper, , France
CHU de Tours
Tours, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Geoffrey URBANSKI
Role: primary
Christophe RICHEZ RICHEZ
Role: primary
Eric HACHULLA
Role: primary
Emmanuelle CAMPANA-SALORT -
Role: primary
Yves ALLENBACH
Role: primary
Guillermo CARVAJAL ALEGRIA
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SATORI (29BRC21.0089)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.